5 Best High Volume Stocks to Invest In According to Hedge Funds

In this article, we will list the 5 Best High Volume Stocks to Invest In According to Hedge Funds. Please visit 10 Best High Volume Stocks to Invest In According to Hedge Funds to see the extended list and the methodology behind it.

5. Pfizer Inc. (NYSE:PFE)

Number of Hedge Fund Holders: 81

Pfizer Inc. (NYSE:PFE) is one of the best high volume stocks to invest in according to hedge funds. On May 5, Pfizer reported a strong start to 2026, achieving Q1 revenues of $14.5 billion, which represents a 2% operational increase compared to the prior-year period. This growth was driven by a 22% operational revenue surge from launched and acquired products, such as Padcev, which saw a 39% increase, and Oncology biosimilars, which rose by 52%. Excluding the declining contributions from COVID-19 products Comirnaty and Paxlovid, Pfizer’s overall revenue grew by 7% operationally.

The company’s R&D pipeline has shown significant momentum, with positive Phase 3 and mid-stage results in key areas like oncology and obesity. Notable developments include the FDA approval of Braftovi for certain colorectal cancers and positive topline results for Elrexfio in multiple myeloma. Pfizer is currently on track to initiate ~20 pivotal studies in 2026, supported by a $2.5 billion investment in internal research and development projects during the first 3 months of the year.

Based on these results, Pfizer Inc. (NYSE:PFE) reaffirmed its full-year 2026 financial guidance, projecting total revenues between $59.5 and $62.5 billion and adjusted diluted EPS in the range of $2.80 to $3.00. Additionally, Pfizer completed the exit of its investment in ViiV Healthcare for $1.875 billion and secured patent settlements for Vyndamax, extending its US patent exclusivity to 2031.

Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company that manufactures, develops, markets, and sells biopharmaceutical products worldwide. It advances wellness, prevention, treatment, and cures in developing and emerging markets, and is also involved in developing immunotherapies that help the immune system to recognise and attack cancer cells.